Antiangiogenic therapy for PTCL
10.3760/cma.j.issn.1673-422X.2012.03.009
- VernacularTitle:外周T细胞淋巴瘤抗血管生成研究进展
- Author:
Shan WAN
;
Kangsheng GU
- Publication Type:Journal Article
- Keywords:
Lymphoma,T-cell,peripheral;
Vascular endothelial growth factors;
Angiogenesis inhibitors;
Thalidomide;
Hypoxia-inducible factor 1
- From:
Journal of International Oncology
2012;39(3):190-193
- CountryChina
- Language:Chinese
-
Abstract:
Peripheral T-cell lymphomas (PTCLs) are insensitive to traditional chemotherapies which lack of effective treatments and have worse prognosis than B-cell lymphomas.Angiogenesis plays an essential role in the malignant tumor growth.Recently,studies have shown that the expression level of VEGF is related to the clinical characteristic and prognosis of PTCL.Novel drugs based on anti-angiogenic theory show curative effect in the preliminary clinical trials for the treatment of PTCL.
